| Home Forums |
|
|||||||
| Drugs and Drug Treatments ATG, Cyclosporine, Revlimid, Vidaza, Dacogen, ... |
 |
|
|
Thread Tools | Search this Thread |
|
#1
Sat Nov 27, 2010, 07:19 PM
|
|||
|
|||
|
Ezatiostat HCL (TLK199 tablets) - A Novel glutathione analog prodrug for MDS
I came across this study titled 'Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome'. (This is the detailed PDF of the study and its results)
The conclusions were as follows - Oral tablet formulation of TLK199 safe and well tolerated in patients with myelodysplastic syndromes (MDS) Adverse effects primarily mild/moderate gastrointestinal events Improvement in erythroid, neutrophil, and platelet cell lines observed after short-course dosing schedule Responses accompanied by clinically meaningful improvement in patient symptoms Majority of patients achieved decreased red blood cell (RBC) transfusion dependence Findings support phase II development of TLK199 in extended dosing schedules (Find the full article here) According to the study, "Of the 23 patients who were RBC transfusion dependent, 8 (35%) achieved transfusion independence and 14 (61%) had a reduction in the RBC transfusion requirements of 4 units/8 weeks (Table 5). One of 5 platelet transfusion–dependent patients achieved independence from platelet transfusions." A Phase II study has been conducted too (given here). Here, "Telik Announces Positive Phase 2 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Patients with Myelodysplastic Syndrome". Very interesting! I also came across this case of "a 77 year old male who received less than two cycles of therapy with ezatiostat HCl which had to be aborted due to intolerable side effects, but which produced a sustained normalization of all three blood counts. This trilineage response has now lasted for more than a year. Interestingly, the patient began with a del(5q) abnormality and responded briefly to lenalidomide. Upon relapse of the anemia, a bone marrow showed the disappearance of the del(5q) but the appearance of a new clonal abnormality t(2;3)." (More details here). Last edited by S001 : Sat Nov 27, 2010 at 07:31 PM. 
|
|
#2
Mon Nov 29, 2010, 06:59 PM
|
|||
|
|||
|
VERY INTERESTING! I hope you stay current with this and keep us up to date.
Thank you!
__________________
Mary, wife of Mike age 70; diagnosed MDS RARS 1999. Tried Vidaza, Revlimid, and Dacogen. SCT 10/1/09 at U of MI; induction FluBu2; sister perfect match donor. 5 years out, little to no GVHD. Off all meds. God is good 
|
|
#4
Tue Nov 30, 2010, 05:43 AM
|
|||
|
|||
|
Tlk199
Hi S001,
If you search this forum you will find that Jordan tried this drug 2007: http://forums.marrowforums.org/showt...ghlight=tlk199 He had problems with very low platelets and the drug didn't increase the platelets so he was taken off the drug. He has not posted since 2008. Kind regards Birgitta-A
|
|
| Thread Tools | Search this Thread |
|
|
